News archive 2009

'Alcohol more harmful than many illegal drugs'

29 Oct 2009, PR 228/09

Alcohol probably poses the biggest drugs harm challenge today, according to a new briefing from the Centre for Crime and Justice Studies. In ‘Estimating drug harms: a risky business’, Professor David Nutt from Imperial College London argues that the relative harm of legal drugs such as alcohol and tobacco is greater than those of a number of illegal drugs, including cannabis, LSD and ecstasy.

Professor Nutt proposes a ‘drug harm ranking’, which compares the harms caused by legal as well as illegal drugs. Alcohol ranks as the fifth most harmful drug after heroin, cocaine, barbiturates and methadone. Tobacco is ranked ninth. Cannabis, LSD and ecstasy, while harmful, are ranked lower at 11, 14 and 18 respectively. Professor Nutt argues that simply focussing on the harms caused by illegal drugs, without assessing them against those of drugs such as alcohol and tobacco, results in an ‘isolated and arbitrary’ debate about relative drug harms.

Professor Nutt argues strongly in favour of an evidence-based approach to drugs classification policy and criticises the ‘precautionary principle’, used by the former Home Secretary Jackie Smith to justify her decision to reclassify cannabis from a class C to a class B drug. By erring on the side of caution, Professor Nutt argues, politicians ‘distort’ and ‘devalue’ research evidence. ‘This leads us to a position where people really don’t know what the evidence is’, he writes.

On cannabis Professor Nutt makes clear that it is ‘a harmful drug’ and argues for a ‘concerted public health response... to drastically reduce its use’. However, he points out that cannabis usage fell when it was reclassified from class B to class C. And he points out that there is ‘a relatively small risk’ of psychotic illness following cannabis use. To prevent one episode of schizophrenia, he argues, it would be necessary ‘to stop 5,000 men aged 20 to 25 from ever using’ cannabis. On recent debates about the classification of ecstasy, in which the Advisory Council on the Misuse of Drugs (ACDM) recommended it be classified as a class B drug, Professor Nutt writes that the ACDM ‘won the intellectual argument, but we obviously didn’t win the decision in terms of classification’.

Professor Nutt also criticises the quality of some research evidence on drug harms. There are, he writes, ‘some horrific examples where some of the so-called “top” scientific journals have published poor quality research about the harms of drugs such as cannabis and ecstasy, sometimes having to retract the articles’.

Among Professor Nutt’s recommendations are:

1. Stopping the ‘artificial separation of alcohol and tobacco as non-drugs’. It will only be possible to assess the real harms of illicit drugs when set alongside the harms of other drugs ‘that people know and use’, he writes.

 2. Improving the public’s general understanding of relative harms. He had previously compared the risks of taking ecstasy over the risks of horse-riding, he writes, because media reporting ‘gives the impression that ecstasy is a much more dangerous drug than it is’.

 3. The provision of ‘more accurate and credible’ information on drugs and the harms they cause. Drug classification based on the best research evidence would ‘be a powerful educational tool’. Basing classification on the desire ‘to give messages other than those relating to relative harms... does great damager to the educational message’, he argues.

Professor Nutt today said: ‘No one is suggesting that drugs are not harmful. The critical question is one of scale and degree. We need a full and open discussion of the evidence and a mature debate about what the drug laws are for – and whether they doing their job?’

Commenting on Professor Nutt’s paper Richard Garside, director of the Centre for Crime and Justice Studies said,  ‘Professor Nutt’s briefing gives us an insight into what drugs policy might look like if it was based on the research evidence, rather than political posturing and moralistic positioning. The Centre for Crime and Justice Studies is a strong advocate of research evidence informing policy making and it is delighted to be publishing this very timely and important contribution by one of the country’s top drugs experts.’

Notes to editors

1. Professor David Nutt is the Edmond J. Safra Chair of Neuropsychopharmacology at Imperial College London and heads up the Psychopharmacology Unit at the University of Bristol. He is also chair of the Advisory Council on the Misuse of Drugs, an independent expert body that advises government on drug related issues in the UK.
 
2. ‘Estimating drug harms: a risky business’, is published on Thursday 29 October 2009. It is available to download from: http://www.crimeandjustice.org.uk/estimatingdrugharms.html The briefing is based on the ‘Eve Saville Lecture’ given by Professor Nutt at King’s College London on 14 July 2009. The Eve Saville Lecture is an annual lecture given by a leading researcher. It was inaugurated by the Centre for Crime and Justice Studies in 1987, in honour of the Centre’s former director.
 
3. The Centre for Crime and Justice Studies at King’s College London is an independent charity that informs and educates about all aspects of crime and criminal justice. It provides information, produces research and carries out policy analysis to encourage and facilitate an understanding of the complex nature of issues concerning crime. It is a membership organisation working with practitioners, policy makers, academics and students, the media and voluntary sector, offering a programme of events, publications and online resources.  http://www.crimeandjustice.org.uk/

King's College London
King's College London is one of the top 25 universities in the world (Times Higher Education 2009) and the fourth oldest in England. A research-led university based in the heart of London, King's has more than 21,000 students from nearly 140 countries, and more than 5,700 employees. King's is in the second phase of a £1 billion redevelopment programme which is transforming its estate.

King's has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 23 departments were ranked in the top quartile of British universities; over half of our academic staff work in departments that are in the top 10 per cent in the UK in their field and can thus be classed as world leading. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly £450 million.

King's has a particularly distinguished reputation in the humanities, law, the sciences (including a wide range of health areas such as psychiatry, medicine and dentistry) and social sciences including international affairs. It has played a major role in many of the advances that have shaped modern life, such as the discovery of the structure of DNA and research that led to the development of radio, television, mobile phones and radar. It is the largest centre for the education of healthcare professionals in Europe; no university has more Medical Research Council Centres.

King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are part of King's Health Partners. King's Health Partners Academic Health Sciences Centre (AHSC) is a pioneering global collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts, including leading teaching hospitals and comprehensive mental health services. For more information, visit: www.kingshealthpartners.org.



Further information


Next:
King’s and Somerset House join forces
Time Magazine Top Ten
New interaction for Breast Cancer Gene
Booker prize winning novelist at King’s
New lung function genes discovered

Previous:
Chair of King’s Health Partners appointed
Minister hosts Prison Studies reception
Pain Management Education ‘inadequate’
hapTEL Dental Virtual Laboratory
Faulty brain 'wiring' triggers schizophrenia onset


This information is provided by the Public Relations Department
Tel: 020-7848 3202  Fax: 020-7848 3739  Email: pr@kcl.ac.uk